We are live on ! Find out more
AIM

AIM ImmunoTech
AIM

30 hedge funds and large institutions have $2.43M invested in AIM ImmunoTech in 2024 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 4

9% less funds holding

Funds holding: 33 → 30 (-3)

23% less capital invested

Capital invested by funds: $3.15M → $2.43M (-$714K)

43% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 7

Holders
30
Holders Change
-3
Holders Change %
-9.09%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
6
Reduced
4
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$120K
2
AC
Armistice Capital
New York
+$84.1K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$21K
4
XT
XTX Topco
Cayman Islands
+$17.2K
5
VF
Virtu Financial
New York
+$15.3K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$46.6K
2
BCM
Bridgeway Capital Management
Texas
-$26K
3
FWM
ForthRight Wealth Management
Georgia
-$7.45K
4
UBS Group
UBS Group
Switzerland
-$7.1K
5
TRCT
Tower Research Capital (TRC)
New York
-$3.83K
Name Holding Trade Value Shares
Change 		Change in
Stake
AC
1
Armistice Capital
New York
$1.17M +$84.1K +2,522 +6%
Vanguard Group
2
Vanguard Group
Pennsylvania
$537K – – –
BlackRock
3
BlackRock
New York
$189K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$125K +$21K +631 +16%
Citadel Advisors
5
Citadel Advisors
Florida
$124K +$120K +3,601 +367%
Renaissance Technologies
6
Renaissance Technologies
New York
$65.7K +$4.83K +145 +6%
State Street
7
State Street
Massachusetts
$46.7K – – –
Verition Fund Management
8
Verition Fund Management
Connecticut
$41.3K – – –
VF
9
Virtu Financial
New York
$28K +$15.3K +459 +82%
Northern Trust
10
Northern Trust
Illinois
$23K – – –
Morgan Stanley
11
Morgan Stanley
New York
$22.8K -$333 -10 -1%
XT
12
XTX Topco
Cayman Islands
$17.8K +$17.2K +515 +355%
SWM
13
SeaCrest Wealth Management
New York
$9.47K – – –
HF
14
HRT Financial
New York
$9K +$11.6K +348 New
CAPTRUST Financial Advisors
15
CAPTRUST Financial Advisors
North Carolina
$5.4K – – –
TRCT
16
Tower Research Capital (TRC)
New York
$4.12K -$3.83K -115 -43%
CB
17
Community Bank
New York
$3.44K – – –
DBRC
18
D.B. Root & Company
Pennsylvania
$3.25K – – –
TCM
19
Traynor Capital Management
Pennsylvania
$3.18K – – –
BCM
20
Bridgeway Capital Management
Texas
$2.97K -$26K -780 -88%
Corient Private Wealth
21
Corient Private Wealth
Florida
$2.7K +$3.33K +100 New
HI
22
Hoey Investments
Pennsylvania
$373 – – –
Osaic Holdings
23
Osaic Holdings
Arizona
$270 – – –
Northwestern Mutual Wealth Management
24
Northwestern Mutual Wealth Management
Wisconsin
$162 +$200 +6 New
Bank of America
25
Bank of America
North Carolina
$116 – – –
1
2

AIM Hedge Fund Activity: Q3 2024 in Review

30 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AIM ImmunoTech (AIM) for Q3 2024, worth a combined $2.43M — down 23% from $3.15M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of AIM and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 6 added.

The largest buyer was Citadel Advisors, adding an estimated $120K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $46.6K sold.

  • 30 institutional investors held AIM ImmunoTech (AIM) as of Q3 2024, down from 33 in Q2 2024.
  • Funds reported $2.43M of AIM ImmunoTech stock for Q3 2024, down 23% quarter-over-quarter.
  • 4 funds opened new AIM ImmunoTech positions in Q3 2024 and 7 closed out, a net change of -3 holders.
  • The largest AIM ImmunoTech buyer in Q3 2024 was Citadel Advisors, an estimated $120K added.
  • The largest AIM ImmunoTech seller in Q3 2024 was Two Sigma Securities, an estimated $46.6K sold.

Based on aggregated 13F filings for Q3 2024.